Gut health may hold key to preventing mania relapse
NCT ID NCT03383874
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether taking a daily probiotic supplement could prevent relapse in people recently hospitalized for mania. Over 24 weeks, 66 participants received either the probiotic or a placebo. The main goal was to see if the probiotic reduced the need for re-hospitalization. Researchers also tracked mood symptoms, thinking skills, and gut bacteria changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Probiotic supplement containing Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis
- What this could lead to
- If it works, this could offer a simple, safe add-on treatment to help people with bipolar disorder stay stable after a manic episode.
- What could go wrong
- This is a small, early-stage trial with only 66 participants, so results may not apply to everyone. The effect may be small or not better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Psychoneuroendocrine Research Program
Dallas, Texas, 75235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can brain implants read and treat bipolar depression without triggering mania?
- Can a 10-Hour eating window stabilize mood in bipolar disorder?
- Gold nanoparticles may make lithium therapy safer and more effective
- Can a new drug calm the storm of bipolar mania?
- Can a new drug calm the storm of bipolar mania?
- Can a common nerve pain drug restore brain chemistry in bipolar cannabis users?